🎒 Gate Square “Blue & White Travel Season” Merch Challenge is here!
📸 Theme: #GateAnywhere🌍
Let’s bring Gate’s blue and white to every corner of the world.
— Open the gate, Gate Anywhere
Take your Gate merch on the go — show us where blue and white meet your life!
At the office, on the road, during a trip, or in your daily setup —
wherever you are, let Gate be part of the view 💙
💡 Creative Ideas (Any style, any format!)
Gate merch displays
Blue & white outfits
Creative logo photography
Event or travel moments
The more personal and creative your story, the more it shines ✨
✅ How to Partici
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.